Aquestive Therapeutics, Inc. (NASDAQ: AQST) has announced significant leadership changes within its executive team. Effective April 2, 2026, Lori J. Braender will step down from her roles as Chief Legal Officer and Chief Compliance Officer, transitioning to a non-executive position as Corporate Secretary. Braender has been with the company for nearly eight years, contributing to its legal and compliance framework. In her place, Thomas A. Zalewski has been appointed as the new Chief Legal Officer and Chief Compliance Officer. Zalewski brings extensive experience in advising life sciences and healthcare companies, having previously served as a Partner and Chair of the Healthcare and Life Sciences practice at Day Pitney LLP. The company expressed confidence in Zalewski's ability to support its mission, particularly in advancing its product Anaphylm, the first oral epinephrine rescue medication, towards FDA approval. Braender will continue to receive her salary through May 7, 2026, and will be entitled to severance benefits under certain conditions. The leadership transition is expected to have a positive impact on the company's strategic direction and operational execution as it continues to innovate in the pharmaceutical space.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.